Ngā hua rapu - Gideon Bollag

Whakamahine hua
  1. 1
    Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity.

    Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. mā Gideon Bollag, Frank McCormick, R Clark

    I whakaputaina 1993
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Discovery of a novel Raf kinase inhibitor.

    Discovery of a novel Raf kinase inhibitor. mā John F. Lyons, S M Wilhelm, Barbara Hibner, Gideon Bollag

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20.

    A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. mā George A. Martin, Gideon Bollag, Frank McCormick, Arie Abo

    I whakaputaina 1995
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

    RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF mā Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity.

    Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. mā Gideon Bollag, Richard A. Roth, Jacqueline Beaudoin, Daria Mochly‐Rosen, D E Koshland

    I whakaputaina 1986
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase

    Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase mā Matthew J. Hart, Sanju Sharma, Nadia elMasry, Rong-Guo Qiu, Peter C. McCabe, Paul Polakis, Gideon Bollag

    I whakaputaina 1996
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition mā Stephen Mok, Jennifer Tsoi, Richard C. Koya, Siwen Hu‐Lieskovan, Brian L. West, Gideon Bollag, Thomas G. Graeber, Antoni Ribas

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations

    Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations mā Suzanne Schubbert, Gideon Bollag, Natalya Lyubynska, Hoa Nguyen, Christian P. Kratz, Martin Zenker, Charlotte M. Niemeyer, Anders Molven, Kevin Shannon

    I whakaputaina 2007
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells

    Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells mā Paolo Salerno, Valentina De Falco, Anna Tamburrino, Tito Claudio Nappi, Giancarlo Vecchio, Rebecca E. Schweppe, Gideon Bollag, Massimo Santoro, Giuliana Salvatore

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma

    The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma mā Peter G. Smith, Fengfei Wang, Kathryn Wilkinson, Kerry J. Savage, Ulf Klein, Donna Neuberg, Gideon Bollag, Margaret A. Shipp, Ricardo C.T. Aguiar

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

    CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer mā Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul J. Priceman, Brian L. West, Gideon Bollag, William H. McBride, Lily Wu

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

    Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice mā Cédric Louvet, Gregory L. Szot, Jiena Lang, Michael R. F. Lee, Nicolas Martinier, Gideon Bollag, Shirley Zhu, Arthur J. Weiss, Jeffrey A. Bluestone

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

    Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy mā Stephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag, Antoni Ribas

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer

    Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer mā Ross A. Okimoto, Luping Lin, Victor Olivas, Elton Chan, Evan Markegard, Andrey Rymar, Dana S. Neel, Xiaohong Chen, Golzar Hemmati, Gideon Bollag, Trever G. Bivona

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer mā Carmelo Nucera, Matthew A. Nehs, Sushruta S. Nagarkatti, Peter M. Sadow, Michal Mekel, Andrew H. Fischer, Paul Lin, Gideon Bollag, Jack Lawler, Richard A. Hodin, Sareh Parangi

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas

    PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas mā John Tayu Lee, Ling Li, Patricia Brafford, Marcia van den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag, Meenhard Herlyn

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

    Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer mā Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma mā William D. Tap, Ke-Wei Gong, Judy Daring, Yiou Tseng, Charles Ginther, Giovanni M. Pauletti, John A. Glaspy, Richard Essner, Gideon Bollag, Peter Hirth, Chao Zhang, Dennis J. Slamon

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

    BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model mā Daniele Perna, Florian A. Karreth, Alistair G. Rust, Pedro A. Pérez–Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis, Mark J. Arends, Marcus Bosenberg, Gideon Bollag, David A. Tuveson, David J. Adams

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

    Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition mā Carlos E. Prada, Edwin Jousma, Tilat A. Rizvi, Jianqiang Wu, R. Scott Dunn, Debra A. Mayes, José A. Cancelas, Eva Dombi, Mi‐Ok Kim, Brian L. West, Gideon Bollag, Nancy Ratner

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: